{"id":"NCT00896298","sponsor":"University of Texas Southwestern Medical Center","briefTitle":"Trial of Leptin Replacement Therapy in Patients With Lipodystrophy","officialTitle":"Double-Blind, Placebo-Controlled Trial of Leptin Replacement Therapy in Patients With Lipodystrophy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-04","primaryCompletion":"2014-11","completion":"2014-11","firstPosted":"2009-05-11","resultsPosted":"2019-03-05","lastUpdate":"2024-03-27"},"enrollment":25,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypoleptinemia","Generalized Lipodystrophy","Partial Lipodystrophy","Insulin Resistance"],"interventions":[{"type":"DRUG","name":"Leptin","otherNames":["Recombinant-methionyl Human Leptin.","r-metHuLeptin"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1 Leptin","type":"ACTIVE_COMPARATOR"},{"label":"2 Sugar pill","type":"PLACEBO_COMPARATOR"}],"summary":"Lipodystrophies represent a therapeutic challenge with regards to insulin resistance, hypertriglyceridemia and fatty liver which often is coupled with significant adipose tissue loss. The purpose of the study is to examine the safety and efficacy of Leptin on subjects with lipodystrophy.","primaryOutcome":{"measure":"Fasting Serum Triglycerides","timeFrame":"4 months","effectByArm":[{"arm":"Leptin Therapy","deltaMin":203,"sd":null},{"arm":"Placebo","deltaMin":304,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2572"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["viral illness, sinusitis, backache","Headaches","Pneumonia","Tonsillectomy","Right Ankle Pain"]}}